US-based molecular diagnostics firm Myriad Genetics has introduced a new medical tool, riskScore, to support its myRisk test developed for hereditary cancer.
riskScore is an algorithm designed to combine genetic markers with a patient’s family and clinical history to quantify the risk of breast cancer development.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The tool will combine data from more than 80 genetic markers called single nucleotide polymorphisms (SNPs) throughout the genome with a family and personal history algorithm called Tyrer-Cuzick model.
Myriad Genetics president and CEO Mark Capone said: “Through the years, Myriad has expanded the number of genes tested and demonstrated.
“Now this new test will provide definitive answers to the 90% of patients testing negative for hereditary cancer genes and will be complimentary to patients tested with myRisk.”
Researchers at the firm initially optimised the genetic markers in riskScore with more than 100,000 patient samples.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe researchers subsequently completed two statistically significant validation studies assessing the tool’s ability to predict the risk of breast cancer in European patients.
The Myriad myRisk Hereditary Cancer test is a 28-gene panel that can identify the risk of breast, ovarian, gastric, colorectal, pancreatic, melanoma, prostate and endometrial cancers.
In addition to a risk assessment, the simple and easy-to-use test delivers specific medical management recommendations to patients who test either positive or negative according to the guidelines of select professional medical societies.
Image: Myriad Genetics researchers. Photo: courtesy of Myriad Genetics Inc.
